<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857529</url>
  </required_header>
  <id_info>
    <org_study_id>IRB18-00197</org_study_id>
    <nct_id>NCT03857529</nct_id>
  </id_info>
  <brief_title>CCFES + tDCS for Motor Control</brief_title>
  <official_title>Contralaterally Controlled FES Plus Transcranial Direct Current Stimulation for Hand Motor Control After Stroke: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study for stroke patients with chronic upper limb hemiplegia will examine the
      effects of non-invasive brain stimulation and neuromuscular electrical stimulation on hand
      motor control and corticospinal excitability. Specifically, this study will investigate the
      effects of timing and delivery of tDCS in conjunction with contralaterally controlled
      functional electrical stimulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corticospinal Excitability</measure>
    <time_frame>up to one hour post intervention</time_frame>
    <description>Change in corticospinal excitability will be measured with transcranial magnetic stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reaction Time</measure>
    <time_frame>up to one hour post intervention</time_frame>
    <description>Change in reaction time will be assessed with visual and auditory cues.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Active tDCS Concurrent With CCFES</condition>
  <condition>Active tDCS Preceding CCFES</condition>
  <condition>Sham tDCS With CCFES</condition>
  <arm_group>
    <arm_group_label>conventional tDCS concurrent with CCFES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unconventional tDCS concurrent with CCFES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional tDCS preceding CCFES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unconventional tDCS preceding CCFES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS with CCFES</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham tDCS preceding and concurrent with CCFES</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation and electrical stimulator</intervention_name>
    <description>Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration.</description>
    <arm_group_label>conventional tDCS concurrent with CCFES</arm_group_label>
    <arm_group_label>conventional tDCS preceding CCFES</arm_group_label>
    <arm_group_label>sham tDCS with CCFES</arm_group_label>
    <arm_group_label>unconventional tDCS concurrent with CCFES</arm_group_label>
    <arm_group_label>unconventional tDCS preceding CCFES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 21

          2. ≥ 6 months since first clinical hemorrhagic or nonhemorrhagic stroke

          3. Able to follow 3-stage commands and remember 2 of 3 items after 30 minutes

          4. Full volitional elbow extension/flexion and hand opening/closing of unaffected limb

          5. Adequate active movement of shoulder and elbow to position the paretic hand in the
             workspace for table-top task practice

          6. Patient must be able to sit unassisted in an armless straight-back chair for the
             duration of the screening portion of the eligibility assessment

          7. Medically stable

          8. ≥ 10° finger extension

          9. Unilateral upper limb hemiparesis with finger extensor strength of ≤ grade 4/5 on the
             manual muscle test AND a score of

             ≥1 and ≤ 11/14 on the hand section of the upper extremity Fugl-Meyer Assessment

         10. Skin intact on hemiparetic arm, hand and scalp

         11. While relaxed, surface neuromuscular electrical stimulation of finger extensors and
             thumb extensors and/or abductors produces a functional degree of hand opening without
             pain.

         12. No significant visual or hearing impairment

        Exclusion Criteria:

          1. Co-existing neurological condition other than prior stroke involving the hemiparetic
             upper limb (e.g., peripheral nerve injury, Parkinson's disease, spinal cord injury,
             traumatic brain injury, multiple sclerosis).

          2. Uncontrolled seizure disorder

          3. Use of seizure lowering threshold medications at the discretion of the study physician
             (Dr. Rich Wilson)

          4. Cardiac pacemaker or other implanted electronic device and/or stent

          5. Pregnant

          6. Intramuscular botox injections in any upper extremity muscle in the last 3 months

          7. Insensate arm, forearm, or hand

          8. Severely impaired cognition and communication

          9. Uncompensated hemi-neglect (extinguishing to double simultaneous stimulation)

         10. Severe shoulder or hand pain (unable to position hand in the workspace without pain)

         11. Metal implant in the head
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayme S Knutson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David A Cunningham, PhD</last_name>
    <phone>(216) 957-3349</phone>
    <email>Dxc536@case.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A Cunningham, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data and results will be made available by request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

